NASDAQ:ADMS - Adamas Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $4.99 -0.06 (-1.19 %) (As of 05/24/2019 04:00 PM ET)Previous Close$4.99Today's Range$4.93 - $5.1552-Week Range$4.93 - $29.49Volume488,018 shsAverage Volume523,691 shsMarket Capitalization$137.39 millionP/E RatioN/ADividend YieldN/ABeta1.35 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. It is also developing ADS-5102 that is in Phase III clinical study to treat walking impairment in patients with multiple sclerosis and other indications; and ADS-4101, which has completed two Phase I studies for treating partial onset seizures in patients with epilepsy. In addition, the company offers Namzaric (memantine hydrochloride extended release and donepezil hydrochloride) capsules for the treatment of moderate to severe dementia of an Alzheimer's type. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California. Receive ADMS News and Ratings via Email Sign-up to receive the latest news and ratings for ADMS and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ADMS Previous Symbol CUSIPN/A CIK1328143 Webhttp://www.adamaspharma.com/ Phone510-450-3500Debt Debt-to-Equity Ratio2.00 Current Ratio7.03 Quick Ratio6.86Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$34.05 million Price / Sales4.03 Cash FlowN/A Price / Cash FlowN/A Book Value$2.32 per share Price / Book2.15Profitability EPS (Most Recent Fiscal Year)($4.87) Net Income$-131,000,000.00 Net Margins-291.22% Return on Equity-122.40% Return on Assets-50.71%Miscellaneous Employees159 Outstanding Shares27,533,000Market Cap$137.39 million Next Earnings Date8/1/2019 (Estimated) OptionableOptionable Adamas Pharmaceuticals (NASDAQ:ADMS) Frequently Asked Questions What is Adamas Pharmaceuticals' stock symbol? Adamas Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMS." How were Adamas Pharmaceuticals' earnings last quarter? Adamas Pharmaceuticals Inc (NASDAQ:ADMS) posted its earnings results on Thursday, May, 9th. The specialty pharmaceutical company reported ($1.08) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($1.13) by $0.05. The specialty pharmaceutical company earned $11.67 million during the quarter, compared to the consensus estimate of $12.78 million. Adamas Pharmaceuticals had a negative net margin of 291.22% and a negative return on equity of 122.40%. View Adamas Pharmaceuticals' Earnings History. When is Adamas Pharmaceuticals' next earnings date? Adamas Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, August 1st 2019. View Earnings Estimates for Adamas Pharmaceuticals. What price target have analysts set for ADMS? 8 brokers have issued twelve-month price objectives for Adamas Pharmaceuticals' shares. Their predictions range from $5.00 to $40.00. On average, they expect Adamas Pharmaceuticals' stock price to reach $22.2857 in the next year. This suggests a possible upside of 346.6% from the stock's current price. View Analyst Price Targets for Adamas Pharmaceuticals. What is the consensus analysts' recommendation for Adamas Pharmaceuticals? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adamas Pharmaceuticals in the last year. There are currently 1 sell rating, 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Adamas Pharmaceuticals. What are Wall Street analysts saying about Adamas Pharmaceuticals stock? Here are some recent quotes from research analysts about Adamas Pharmaceuticals stock: 1. According to Zacks Investment Research, "Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products. Adamas is currently developing ADS-5102, its lead wholly-owned product candidate, for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson's disease and for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment. The company's portfolio also includes Namzaric and Namenda XR, two approved products with Forest Laboratories Holdings Limited, an indirect wholly-owned subsidiary of Allergan plc. Forest is responsible for marketing both products in the United States under an exclusive license from Adamas. " (5/22/2019) 2. Northland Securities analysts commented, "We remain confident in GOCOVRI’s success, along w/ significant upside potential from ADS-5102 for MS walking impairment. GOCOVRI sales for ’18 totaled $34MM, comparing to $22.5MM at the time of our initiation of coverage in late-2017. While sequential Rx growth has slowed, we anticipate sustained sequential growth supporting our OP rating. Adamas reported 4Q results w/ GOCOVRI sales at $13.3MM, aligned with guidance provided in early-January. Paid prescriptions for the 4Q period totaled 5,730, up sequentially from 4,740. R&D and SG&A expense line items totaled $10.6MM and $27.6MM, respectively, which were lower than expected. EPS tracked ($1.06) vs. the consensus of ($1.33), attributable to lower-than-anticipated operating expenses. The Co. ended the December 31st 2018 period w/ cash of $211MM, w/ cash used in the 4Q period ~$22MM." (3/5/2019) Has Adamas Pharmaceuticals been receiving favorable news coverage? News articles about ADMS stock have trended somewhat positive recently, InfoTrie Sentiment reports. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Adamas Pharmaceuticals earned a daily sentiment score of 1.6 on InfoTrie's scale. They also assigned media stories about the specialty pharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the immediate future. Who are some of Adamas Pharmaceuticals' key competitors? Some companies that are related to Adamas Pharmaceuticals include Dermira (DERM), Urogen Pharma (URGN), Basilea Pharmaceutica (BPMUF), Revance Therapeutics (RVNC), Akorn (AKRX), GlycoMimetics (GLYC), Synthorx (THOR), MediciNova (MNOV), NuCana (NCNA), Flexion Therapeutics (FLXN), CytomX Therapeutics (CTMX), Corbus Pharmaceuticals (CRBP), Vital Therapies (VTL), Evolus (EOLS) and Milestone Pharmaceuticals (MIST). What other stocks do shareholders of Adamas Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Adamas Pharmaceuticals investors own include Rite Aid (RAD), Sangamo Therapeutics (SGMO), Dynavax Technologies (DVAX), Exelixis (EXEL), Flexion Therapeutics (FLXN), Omeros (OMER), Synergy Pharmaceuticals (SGYP), ACADIA Pharmaceuticals (ACAD), Cara Therapeutics (CARA) and Century Aluminum (CENX). Who are Adamas Pharmaceuticals' key executives? Adamas Pharmaceuticals' management team includes the folowing people: Dr. Gregory T. Went, Co-Founder, Chairman & CEO (Age 55)Mr. Alfred G. Merriweather, Chief Financial Officer (Age 65)Mr. Christopher B. Prentiss, Chief Accounting Officer (Age 44)Ashleigh Barreto, Director of Corp. Communications & Investor RelationsMs. Jennifer J. Rhodes, Chief Bus. Officer, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 49) Who are Adamas Pharmaceuticals' major shareholders? Adamas Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Macquarie Group Ltd. (9.52%), Broadfin Capital LLC (8.97%), BlackRock Inc. (7.57%), Emerald Advisers LLC (2.28%), Deltec Asset Management LLC (1.96%) and Northern Trust Corp (0.98%). Company insiders that own Adamas Pharmaceuticals stock include Alfred G Merriweather, Christopher B Prentiss, Great Point Partners Llc, Gregory T Went, Jennifer J Rhodes, Rajiv Patni and Richard King. View Institutional Ownership Trends for Adamas Pharmaceuticals. Which major investors are selling Adamas Pharmaceuticals stock? ADMS stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Citigroup Inc., Broadfin Capital LLC, Macquarie Group Ltd., SCP Investment LP, Wells Fargo & Company MN, Emerald Advisers LLC and New York State Common Retirement Fund. Company insiders that have sold Adamas Pharmaceuticals company stock in the last year include Alfred G Merriweather, Christopher B Prentiss, Gregory T Went, Jennifer J Rhodes and Richard King. View Insider Buying and Selling for Adamas Pharmaceuticals. Which major investors are buying Adamas Pharmaceuticals stock? ADMS stock was acquired by a variety of institutional investors in the last quarter, including Deltec Asset Management LLC, Healthcare Value Capital LLC, Rice Hall James & Associates LLC, Granite Investment Partners LLC, Dimensional Fund Advisors LP, Fosun International Ltd, Creative Planning and BlackRock Inc.. View Insider Buying and Selling for Adamas Pharmaceuticals. How do I buy shares of Adamas Pharmaceuticals? Shares of ADMS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Adamas Pharmaceuticals' stock price today? One share of ADMS stock can currently be purchased for approximately $4.99. How big of a company is Adamas Pharmaceuticals? Adamas Pharmaceuticals has a market capitalization of $137.39 million and generates $34.05 million in revenue each year. The specialty pharmaceutical company earns $-131,000,000.00 in net income (profit) each year or ($4.87) on an earnings per share basis. Adamas Pharmaceuticals employs 159 workers across the globe. What is Adamas Pharmaceuticals' official website? The official website for Adamas Pharmaceuticals is http://www.adamaspharma.com/. How can I contact Adamas Pharmaceuticals? Adamas Pharmaceuticals' mailing address is 1900 POWELL ST. SUITE 1000, EMERYVILLE CA, 94608. The specialty pharmaceutical company can be reached via phone at 510-450-3500 or via email at [email protected] MarketBeat Community Rating for Adamas Pharmaceuticals (NASDAQ ADMS)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 320 (Vote Outperform)Underperform Votes: 273 (Vote Underperform)Total Votes: 593MarketBeat's community ratings are surveys of what our community members think about Adamas Pharmaceuticals and other stocks. Vote "Outperform" if you believe ADMS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADMS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/25/2019 by MarketBeat.com StaffFeatured Article: Why investors pay attention to retained earnings Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.